Bolt Biotherapeutics, Inc. (BOLT)
$4.29+1.18%Close
BUYRECOVERY · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $8M
- Beta
- 1.01
- P/E (TTM)
- -0.27
- Short % float
- 1.64%
- Days to cover
- 1.0
- SI change
- +39.2%
- 1W
- +22.22%
- 1M
- +7.79%
- vs SPY 1W
- +21.80%
- vs SPY 1M
- +5.73%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 2
- VALUE
- 8
- GROWTH
- 35
- GARP
- 1
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-75.7%
REV YoY-
ROE-126.2%
EPS YoY-
ROA-71.2%
GROSS96
OP-623
NET-611
[VALUATION]
P/E TTM-0.27
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.57
P/FCF-
EV/EBITDA-0.61
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E171.08
ALTMAN Z-
CURR RATIO2.61
ND/EBITDA-
BETA1.01
Company news
FAQ
- What is LOPJLB’s current signal on BOLT?
- LOPJLB’s latest quantitative signal on Bolt Biotherapeutics, Inc. (BOLT) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is BOLT in?
- Bolt Biotherapeutics, Inc. (BOLT) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Bolt Biotherapeutics, Inc. (BOLT) do?
- Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HE…